Piramal Pharma reported a significant increase in consolidated net profit for Q2, growing from Rs 5 crore last year to Rs 23 crore. Revenue also rose to Rs 2,242 crore. Key drivers include strong growth in the CDMO and CHG businesses, with expansion plans in Lexington, Dahej, and Digwal to meet rising demand.
| Subscribe To Our Free Newsletter |
